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Abstract: The Golgi complex lies at the heart of the secretory pathway and is responsible 
for modifying proteins and lipids, as well as sorting newly synthesized molecules to their 
correct destination. As a consequence of these important roles, any changes in its proteome 
can negatively affect its function and in turn lead to disease. Recently, a number of proteins 
have been identified, which when either depleted or mutated, result in diseases that affect 
various organ systems. Here we describe how these proteins have been linked to the Golgi 
complex, and specifically how they affect either the morphology, membrane traffic or 
glycosylation ability of this organelle.  
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1. Introduction 
Higher eukaryotic cells have evolved a highly compartmentalized endomembrane system in order to 
both increase efficiency and diversity of the biochemical processes that they can perform. In order to 
ensure that the correct complement of proteins and lipids necessary to maintain cellular homeostasis 
are present in each organelle, highly discrete membrane trafficking pathways connecting the various 
membrane-bounded organelles exist. Disruption of specific transport steps between the endoplasmic 
reticulum (ER), Golgi complex, endosomal-lysosomal system and the plasma membrane all can have 
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dramatic consequences on the cell, and increasingly defects in the molecular machinery regulating 
membrane traffic are being linked to hereditary diseases [1,2]. 
In mammalian cells the Golgi complex has a distinct architecture [3,4], which at the ultrastructural 
level is characterized by a series of long ribbon-like membranes tightly opposed to one another. At the 
macro level this organelle is usually positioned centrally in the cell, close to the nucleus, and as such is 
considered as having a juxta-nuclear localization. In addition to its physical location at the center of the 
cell, this organelle also lies at the heart of the trafficking routes running through the endomembrane 
system. In the case of the secretory pathway it both receives newly synthesized proteins from the ER, 
and subsequently exports these same proteins to the endosomal-lysosomal system and the cell surface. 
During transit through the Golgi complex key modifications are made to most proteins, including 
changes to their glycosylation profile, sulfation, phosphorylation, and also proteolytic cleavage. As 
such, if Golgi homeostasis is perturbed then this is likely to affect its function, which in turn may result 
in disease. Several Golgi-related diseases have been identified, but the last few years have seen an 
increase in the identification of novel disease-related genes. Here, we focus our attention on several of 
these genes, and discuss the major phenotypes with respect to the Golgi complex: trafficking, 
morphological changes, glycosylation defects and finally loss-of-function of Golgi-residents. 
2. When Traffic Comes to a Halt 
Due to its central role in the secretory pathway, it is expected that any changes to the proteome of 
the Golgi complex would affect its homeostasis and consequently the flux of proteins trafficking 
through it. In recent years several diseases have been linked in various ways with trafficking at the 
Golgi, both in terms of receiving material from the ER, and also in the retrograde direction recycling 
components back to the ER. However, disentangling whether the transport defect is anterograde or 
retrograde is often difficult as both pathways are highly dependent on each other. One recent example 
of a molecule affecting transport at this level is the proteolipid protein 1 (PLP1), which is one of the 
main components of myelin. Mutations in PLP1 have been connected to a wide spectrum of 
hypomyelinating disorders such as Pelizaeus-Merzbacher disease [5]. In this disease, mutant PLP1 is 
misfolded and accumulates in the ER, which in turn inhibits Golgi-to-ER retrograde trafficking. As a 
consequence, chaperones harboring a KDEL motif and recycling between the ER and Golgi complex 
become depleted from the ER and accumulate in the cis-Golgi thereby leading to Golgi complex 
fragmentation [6]. Another neurodegenerative disease that also has at its core changes in membrane 
trafficking is proximal spinal muscular atrophy. In normal cells, the SMN1 gene encodes the survival 
of motor neuron 1 protein, involved in snRNP assembly and which has been shown to move along the 
neuronal axon in granules. However, in proximal spinal muscular atrophy, which results from the loss 
of expression of SMN1, a global blockade of granule export from the trans-Golgi network is observed, 
and granule accumulation occurs. This ultimately results in decreased levels of SMN1 in neurites and 
corresponding growth cone defects [7].  
Other cell and tissue types are also sensitive to the blockage of trafficking from the Golgi complex. 
For example, dyschromatosis universalis hereditaria is a disorder characterized by the appearance of 
asymptomatic hyper- and hypo-pigmented macules in the skin. Recently three missense mutations 
have been identified in the ATP-binding cassette sub-family 8 member 6 (ABCB6) gene, which   Int. J. Mol. Sci. 2013, 14  18672 
 
 
codes for a protein expressed in the epidermis and which is normally localized to endosome-like 
compartments and to the dendrite tips. All mutations led to retention of the protein in the Golgi 
complex [8], but it is unclear currently as to whether this is due to a general block in membrane 
trafficking or if the mutations affect the targeting of this protein only. 
3. When Shape Changes 
One possible consequence of mutations in Golgi complex proteins is that they cause gross changes 
in the morphology of the entire organelle and protein mislocalization, which together result in 
functional problems such as impairment of glycosylation. However, it is still unclear as to the 
importance of the physical integrity of this organelle with respect to its various functions. For example, 
live cell imaging experiments have shown that in the presence of the microtubule disrupting agent 
nocodazole, which also fragments the Golgi complex, secretory traffic between the ER and Golgi 
complex is initially retarded [9], although with prolonged nocodazole treatment transfer of material 
from ER to Golgi is restored [10]. By contrast, in nocodazole-treated cells, Golgi complex to cell 
surface transport still occurs with normal kinetics [11]. Nevertheless, there are examples where 
morphological changes to this organelle can have functional consequences and linkage to disease can 
be found. In a cellular model of Parkinson’s disease in PC12 cells, the Golgi fragmentation that is 
observed has been found to be dependent on the expression levels of certain members of the Rab 
family of small GTP binding proteins [12]. At the cellular level, Parkinson’s disease is associated with 
the accumulation of the pre-synaptic protein α-synuclein, and a block in ER-Golgi transport [13]. In 
this new study, fragmentation was correlated with changes in levels of RAB1, RAB2, RAB8 and the 
SNARE fusion protein syntaxin-5 (STX5), but that the phenotype could be rescued when RAB1 and 
RAB8 were overexpressed and RAB2 and STX5 were depleted [12]. All these proteins are well 
established early secretory pathway machinery molecules, however this study indicated that the   
Golgi fragmentation occurred prior to α-synuclein aggregation and might indeed promote it, thereby 
leading to the formation of the inclusion bodies. Other Rab proteins of the Golgi complex are also 
implicated in disease; mutations in RAB33B have recently been shown to lead to Golgi swelling   
and fragmentation in Smith-McCort dysplasia [14]. Although further experiments are still required, 
imaging approaches focusing on Rab behavior in living cells [15] are highly likely to further our 
understanding of these key membrane traffic molecules in disease.  
Proteins that modulate the function of members of the Rab family of proteins have also been 
involved in the pathogenesis of Golgi-related diseases. The Ras and Rab interactor 2 (RIN2) protein, a 
guanine nucleotide exchange factor for the early endocytic pathway regulator RAB5 [16], has been 
found to be at the heart of two related connective tissue disorders, namely macrocephaly, alopecia, 
cutis laxa and scoliosis (MACS) syndrome and the RIN2 syndrome [17,18]. In these diseases, two 
independent frameshift mutations that lead to a decrease in mRNA expression levels and absence of 
the protein in patients’ fibroblasts were described. In the case of the MACS syndrome, the authors 
report an accumulation of vacuoles in the Golgi, but no other changes to the organelle [17]. By 
contrast, in RIN2 syndrome, dilation of the ER and rarified and dilated Golgi cisternae were   
observed [18]. In the latter, impairment of trafficking from the ER to the Golgi complex and from the 
Golgi to the plasma membrane were also detected, demonstrating that the consequences of the Int. J. Mol. Sci. 2013, 14  18673 
 
 
mutations affect the organelle in more than one way. Techniques such as RNA interference (RNAi) in 
cultured mammalian cells should further help us understand the cellular consequences of changes in 
proteins such as RIN2. At the macro level, immunofluorescence studies clearly show that the depletion 
of RIN2 indeed affects the overall morphology of the Golgi complex, when compared to control cells 
(Figure 1). Deeper analysis of data from large-scale RNAi studies looking at secretory pathway 
function [19] and Golgi morphology [20] will inevitably provide more candidates associated with 
Golgi morphology and function, which may be linked to disease. 
Figure 1. Immunofluorescence showing gross changes in Golgi complex morphology in 
response to the down-regulation of particular proteins. HeLa cells were incubated with 
RNAi reagents targeting RIN2, TMEM165 or DMD and incubated for 48 h. Cells were 
fixed and stained for the Golgi matrix protein GM130 (green) and the nucleus (blue). A 
normal compact juxta-nuclear Golgi complex can be seen in control cells, whereas the  
cells depleted for the three proteins of interest show varying degrees of change in Golgi 
complex morphology. Scale bar corresponds to 10 μm.  
 
One final recent example reporting a potential link between a Golgi complex protein and disease is 
centered on the previously uncharacterized transmembrane protein TMEM165. This protein may be 
involved in proton/calcium transport, and has been found to be linked to congenital disorders of type II 
glycosylation [21–23]. Four different disease-causing mutations that lead to decreased protein 
expression have been identified in TMEM165, one of which results in alternative splicing of the 
mRNA with no expression of the mutant protein [21]. The wild-type protein was found to localize to 
the Golgi complex and also to the endosomal-lysosomal system, whereas each of the four mutants 
analyzed were found in different locations in the cell [23]. The fact that the Golgi complex appears to 
be swollen and that the trans-Golgi network is fragmented has been suggested to indicate that this Int. J. Mol. Sci. 2013, 14  18674 
 
 
protein is involved in maintenance of the morphology of the organelle [21]. Cellular depletion of 
TMEM165 using RNAi appears only to have a mild effect on the Golgi complex at the macro   
level (Figure 1).  
4. When Glycosylation Is Impaired 
The literature regarding diseases of glycosylation has been extensively reviewed elsewhere [24–27]. 
Nevertheless, since almost all proteins passing through the secretory pathway undergo some form  
of glycosylation, it is highly likely that there are still more diseases associated with this process to  
be discovered. Defects in protein glycosylation lead to diseases of varied etiology ranging   
from muscular [28] to multi-system disorders such as the conserved oligomeric Golgi (COG)   
complex-dependent human glycosylation disorders [26]. Of note is the fact that the detection of   
these diseases is often serendipitous and those identified so far are primarily severe syndromes some  
of which are even fatal. Although many glycosylation disorders are caused by loss-of-function 
mutations in glycosyltransferases or sugar transporters, mutations have also been described in proteins 
associated with the COG complex, a multi-protein assembly involved in vesicle trafficking processes 
at the Golgi complex. 
A small number of diseases have been described that result from a change in the acidification of the 
Golgi complex. Increases in the intra-luminal Golgi pH disrupts morphology of the organelle, affects 
protein and lipid processing and glycosylation, and alters cargo sorting [29]. In Angelman syndrome, a 
severe and rare neurodevelopmental disorder, it has been reported that the lack of ubiquitin protein 
ligase E3A (UBE3A) expression leads to an increase in the Golgi pH, which in turn causes osmotic 
swelling of the Golgi cisternae with a concurrent reduction in protein sialylation, a process highly 
dependent on pH [30]. Cutis Laxa type II and wrinkly skin syndrome, diseases that affect the 
connective tissue, and in particular the skin, are caused by mutations to ATP6V0A2, a vacuolar ATPase 
that is localized to the Golgi complex and is involved in its acidification [31,32]. Although the exact 
mechanisms by which these mutations cause the disease still remain to be established, one can 
speculate that perturbations to the intra-luminal Golgi pH will inevitably lead to abnormal protein 
glycosylation and possible aberrant Golgi trafficking [33]. 
Interestingly, there are also likely to be further links discovered between defects in glycosylation 
and aberrant Golgi complex morphology. This is because in order for glycosylation events to be tightly 
regulated, distinct classes of glycosylation enzyme need to be physically partitioned from one another, 
and therefore any morphological rearrangements of the individual cisternae may compromise this 
situation. As described above, mutations in TMEM165 induce morphological changes in the Golgi 
complex, however in addition the authors of these studies also describe a reduction in protein 
glycosylation [21,22]. Since the function of numerous proteins involved in bone metabolism or 
belonging to the extracellular matrix can be affected by abnormal glycosylation, impairment of this 
process provides one explanation for the skeletal manifestations observed in the disease [34].  
5. When Function Is Lost 
Finally, we address the issue of the effects that can be caused when the expression of a Golgi-resident 
protein is lost due to mutation. Perhaps the most well-known case is in Duchenne muscular dystrophy, Int. J. Mol. Sci. 2013, 14  18675 
 
 
where the dystrophin (DMD) protein is not expressed leading to aberrant Golgi organization [35] 
(Figure 1). However, because this particular condition has been recently reviewed elsewhere [36], we 
will focus our attention on other Golgi complex proteins, the loss of which induces disease.  
The first example is RAB33B, a member of the Rab family of small GTP binding proteins, which is 
localized to the Golgi complex and has been proposed to be involved in retrograde traffic back to the 
ER [37,38] and also more recently has been connected to autophagy [39,40]. Two missense mutations 
in the GTPase domain of RAB33B have been identified in patients with two different skeletal 
dysplasias. Interestingly in Dyggve-Melchior-Clausen disease no changes were detected at the level of 
the Golgi complex [41], whereas in Smith-McCort Dysplasia reduced RAB33B protein expression 
levels were correlated with a swollen and fragmented Golgi complex [14]. Another observation is that 
the mutation found in Dyggve-Melchior-Clausen disease occurs at a lysine residue that is conserved in 
RAB33B orthologs across all species [41]. In fact, this lysine residue is found in the GTP binding 
pocket of all Rab family members thereby demonstrating the importance of this residue to the function 
of the protein. Of note is the fact that both diseases can also be caused by mutations to another   
Golgi-resident protein, dymeclin [42], and so further studies will be needed to establish for these 
diseases the relationship between this protein and RAB33B. 
A second example of loss of expression of a Golgi protein is also seen with another member   
of the Rab GTPase family. In X-linked Mental retardation associated with autism, epilepsy and 
macrocephaly one study has found two different loss-of-function mutations in RAB39B. This particular 
Rab protein was originally described as being expressed in a wide variety of tissues [43], although this 
more recent study highlights its role in the Golgi complex of neuronal cells [44]. Both reported 
mutations result in loss of protein expression in neurons, which in turn leads to an altered number and 
morphology of neurite growth cones and reduction of presynaptic buttons [44]. This work is important 
not only with respect to the elucidation of the disease mechanisms, but is also useful to begin to 
understand the function of RAB39B at the cellular level. Indeed the results suggest that this protein is 
somehow involved in the development of neurons and human intellectual ability. 
Another example also with potential functional links to the Rab family is SCYL1BP1/GORAB, a 
RAB6-interacting golgin. Mutations in this gene were found to cause Gerodermia osteodysplastica [45,46]. 
Most of the mutations identified in this gene lead to a loss of protein expression, however in one 
affected family the mutation still led to protein expression but the function was lost [46]. In all cases 
no detectable changes in Golgi complex morphology were found.  
One final example is GOSR2, a Golgi-resident Qb-SNARE involved in intra-Golgi trafficking, 
which has been linked to “North Sea” progressive myoclonus epilepsy, a progressive neurodegenerative 
disease associated with skeletal deformities [47,48]. The authors of this study describe a missense 
mutation in a glycine residue conserved across species and present in all three GOSR2 isoforms. 
Although this mutation still leads to protein expression, it fails to localize to the Golgi complex. In 
addition, studies performed with a yeast strain lacking the GOSR2 ortholog demonstrate that 
overexpression of the mutant protein is unable to rescue the phenotype and the cells die, suggesting 
that the disease-associated mutation is equivalent to a loss-of-function mutation [47]. 
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6. Conclusions  
The last five years have seen a significant number of human diseases being linked to Golgi complex 
proteins (Table 1). Not only are these discoveries important from a health perspective, but also they 
provide an additional avenue of insight for us to understand the function of this organelle at the 
molecular and cellular level through to the organismal level. Although the list of proteins that we have 
assembled here is far from complete, it is becoming clear that the number of disease-related proteins 
linked to Golgi homeostasis may eventually rival those known to be important for diseases associated 
with other key organelles such as the ER [49,50] and lysosomes [51].  
Table 1. Proteins of the Golgi complex associated with disease.  
Affected gene  Disease 
Primary clinical 
manifestation 
Comments/Cellular effect/Reference 
ABCB6 
Dyschromatosis 
universalis hereditaria 
Skin disorder 
Mutation leads to retention of the protein 
in the Golgi [8] 
ATP6V0A2  Cutis laxa 
Connective tissue 
disorder 
Mutations lead to abnormal glycosylation 
of serum proteins (CDG-II) and 
impairment of Golgi trafficking [31–33] 
ATP7A 
Menkes disease, 
occipital horn syndrome 
Neurodegeneration 
and connective 
tissue disorder 
Protein is localized to the TGN and is 
essential for copper metabolism. A wide 
variety of reported mutations affect its 
localization and trafficking pathways 
through the Golgi [52] 
ATP7B  Wilson disease 
Hepatic and 
neurological 
disorders 
Protein is localized to the TGN and is 
essential for copper metabolism. A wide 
variety of reported mutations affect its 
localization and trafficking pathways 
through the Golgi [53] 
COG1, COG4, 
COG5, COG6, 
COG6, COG7, 
COG8 
Congenital disorders of 
glycosylation 
Multi-system 
disorders 
Typically reduced levels of the COG 
member occur, leading to defects in 
glycosylation [26] 
DMD 
Duchenne muscular 
dystrophy 
Muscular disease 
Absence of DMD leads to aberrant 
organization of the Golgi [35] 
FGD1 
Aarskog-Scott 
syndrome/faciogenital 
dysplasia 
Skeletal and genital 
abnormalities 
Localized to the TGN with mutants 
causing a reduction in trafficking from 
the Golgi [54] 
GOSR2 
“North Sea” progressive 
myoclonus epilepsy 
Neurological disease 
Mutant protein fails to localize to the  
cis-Golgi [47,48] 
PLP1 
Pelizaeus-Merzbacher 
disease 
Neurological disease 
Mutation in PLP1 leads to depletion of 
ER Chaperones with a KDEL motif and 
Golgi fragmentation [6] 
RAB1, RAB2, 
RAB8, STX5 
Parkinson’s disease  Neurological disease 
Altered expression of the proteins leads 
to Golgi fragmentation [12] 
RAB33B 
Dyggve-Melchior-
Clausen disease 
Skeletal dysplasia 
Missense mutation leads to decreased 
protein expression [41] 
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Table 1. Cont. 
Affected gene  Disease 
Primary clinical 
manifestation 
Comments/Cellular 
effect/Reference 
RAB33B 
Smith-McCort 
Dysplasia 
Skeletal dysplasia 
Missense mutation leads to lower 
protein expression and swollen and 
fragmented Golgi in many cells [14] 
RAB39B 
X-linked mental 
retardation associated 
with autism, epilepsy 
and macrocephaly 
Neurological disease 
Loss of function mutations in 
RAB39B lead to altered number and 
morphology of neurite growth cones 
and reduction of presynaptic  
buttons [44] 
RIN2 
Macrocephaly, 
alopecia, cutis laxa 
and scoliosis (MACS) 
syndrome 
Connective tissue 
disorder 
Loss of function mutation leads to 
presence of vacuoles in the  
Golgi [17] 
RIN2  RIN2 syndrome 
Connective tissue 
disorder 
Loss of function mutation leads to 
dilation of ER, and rarified and 
dilated Golgi cisternae [18] 
SCYL1BP1/GORAB 
Gerodermia 
osteodysplastica 
Connective tissue 
disorder 
Loss of function mutation [45,46] 
SMN 
Proximal spinal 
muscular atrophy 
Neurological disease 
Decreased expression of SMN leads 
to accumulation of SMN granules in 
the trans-Golgi network and a global 
blockage of granule secretion [7] 
TMEM165 
Congenital disorder of 
glycosylation type II 
(CGD-II) 
Psychomotor 
retardation and bone 
dysplasia 
Mutation leads to lower protein 
expression and altered subcellular 
localization with overall Golgi 
swelling and fragmented trans-Golgi 
network. Decreased protein 
glycosylation is also observed [21–23] 
UBE3A  Angelman syndrome 
Neurodevelopmental 
Disorder 
Loss of protein expression leads to an 
altered Golgi morphology and pH, 
which is associated with a reduction 
in protein sialylation [30] 
Many of the proteins that we highlight in this review are unsurprisingly associated with trafficking 
through the Golgi complex (e.g., the Rab family of proteins), while others play a role in maintaining 
the homeostasis of the organelle (e.g., ATP6V0A2). One challenge however, is to unravel the cause 
and effect of each cellular phenotype. For example, mutation of a transporter of the Golgi complex 
may affect the luminal pH, which in turn affects the glycosylation efficiencies of particular   
enzymes, which then ultimately may alter the flux of all proteins passing through the organelle. 
Conversely, defects in a proteins associated with trafficking may cause morphological changes to the 
organelle, which in turn may affect specific biochemical or enzymatic reactions requiring a discrete 
micro-environment. To date, only in a few cases has it been possible to precisely link the protein to a 
particular phenotype, whereas in many more cases how the etiology of the disease is derived from the 
cellular events remains to be established. Nevertheless, the identification of disease causing mutations 
in specific proteins is very useful to physicians as it allows them to perform more accurate diagnoses 
and ultimately provide better advice to affected families. However, there is still much to be done, as in Int. J. Mol. Sci. 2013, 14  18678 
 
 
the majority of the reports that we highlight here, only a limited amount of molecular and cellular 
information has been gathered. Indeed for many of these proteins now linked to disease we still do  
not know their fundamental biochemical characteristics at the cellular level—for example are they 
degraded more rapidly than the wild-type protein, do they aggregate, or are protein-protein interactions 
impaired? Only a more complete knowledge of the molecular basis of the disease will ultimately allow 
appropriate therapies to be developed. Another obstacle to the elucidation of the molecular 
mechanisms of many of these diseases is that they affect organ systems that are challenging to work 
with, such as the central nervous system. In addition, the limited availability of patient tissues (as many 
of these disorders are rare) is also problematic.  
In the forthcoming years it is to be expected that further disease causing mutations will be identified 
in proteins that physically and functionally are associated with the Golgi complex. More than 100 years 
after the discovery of this organelle, it is only now that we are beginning to realize the importance of 
the Golgi complex in cells throughout the human body, and the critical role that it plays at the heart of 
the endomembrane system. 
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